Dmitry Balyasny’s Acadia Pharmaceuticals ACAD Stock Holding History

Dmitry Balyasny’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100,000	Closed	-$1.66M	–	2742
2025 Q1	$1.66M	Buy	+100,000	New	+$1.82M	﹤0.01%	1789
2024 Q3	–	Sell	-200,000	Closed	-$3.25M	–	2684
2024 Q2	$3.25M	Buy	+200,000	New	+$3.23M	0.01%	1352
2024 Q1	–	Sell	-100,000	Closed	-$3.13M	–	2557
2023 Q4	$3.13M	Buy	+100,000	New	+$2.39M	0.01%	1301
2020 Q4	–	Sell	-150,000	Closed	-$6.19M	–	1268
2020 Q3	$6.19M	Buy	+150,000	New	+$6.48M	0.05%	534
2018 Q4	–	Sell	-55,000	Closed	-$831K	–	1348
2018 Q3	$831K	Buy	+55,000	New	+$865K	﹤0.01%	1234
2017 Q3	–	Sell	-150,000	Closed	-$4.18M	–	1836
2017 Q2	$4.18M	Buy	+150,000	New	+$4.47M	0.02%	791

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dmitry Balyasny's ACAD Position: Q2 2026 in Review

Dmitry Balyasny increased its Acadia Pharmaceuticals (ACAD) stake by 24% in Q2 2026, buying an estimated $1.65M and bringing the position to 388,024 shares worth $9.82M. The position accounts for 0.01% of the portfolio, ranked #1063.

Dmitry Balyasny first reported a position in ACAD in Q4 2016 and has held it in 19 quarters since. The position peaked at $26.1M in Q3 2018. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Dmitry Balyasny held 388,024 shares of Acadia Pharmaceuticals worth $9.82M as of Q2 2026.
Dmitry Balyasny bought 75,042 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
Acadia Pharmaceuticals made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1063 holding.
Dmitry Balyasny first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
Dmitry Balyasny's Acadia Pharmaceuticals position peaked at $26.1M in Q3 2018.
350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.